Bank of New York Mellon’s Eledon Pharmaceuticals ELDN Stock Holding History

Bank of New York Mellon's ELDN Position: Q2 2026 in Review

Bank of New York Mellon increased its Eledon Pharmaceuticals (ELDN) stake by 16% in Q2 2026, buying an estimated $82.8K and bringing the position to 166,927 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #3606.

Bank of New York Mellon first reported a position in ELDN in Q4 2014 and has held it in 15 quarters since. The position peaked at $6.68M in Q3 2015. 72 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

• Bank of New York Mellon held 166,927 shares of Eledon Pharmaceuticals worth $658K as of Q2 2026.
• Bank of New York Mellon bought 22,779 Eledon Pharmaceuticals shares in Q2 2026, an estimated $82.8K.
• Eledon Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3606 holding.
• Bank of New York Mellon first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 15 quarters since.
• Bank of New York Mellon's Eledon Pharmaceuticals position peaked at $6.68M in Q3 2015.
• 72 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.